Disease-Modifying Effects of a Novel Cathepsin K Inhibitor in Osteoarthritis: A Randomized, Placebo-Controlled Study.

Conclusion: MIV-711 was not more effective than placebo for pain, but it significantly reduced bone and cartilage progression with a reassuring safety profile. This treatment may merit further evaluation as a disease-modifying osteoarthritis drug.
Primary Funding Source: Medivir.
PMID: 31887743 [PubMed - as supplied by publisher]

Source: Annals of Internal Medicine - December 30, 2019 Category: Internal Medicine Authors: Conaghan PG, Bowes MA, Kingsbury SR, Brett A, Guillard G, Rizoska B, Sjögren N, Graham P, Jansson Å, Wadell C, Bethell R, Öhd J Tags: Ann Intern Med Source Type: research